Database

Startups

Main Industry
Health Care
Main Product/Service
Medical Device Development
The content above was translated by Ai
Founded Year
2018
Unified Business No.
50780070
Status
Active
Number of Employees
0
Total Paid-in Capital
1,700,000 (NT$)
Location of Company
Taiwan , Kaohsiung City
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups. Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed. Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
About the Company
LukeMed was founded in 2017, focusing on the development of medical devices and the core proposition of making the medical environment safer. We have established the goal of building a healthcare platform that integrates mobile, digital health, and cloud services.

Our goal is to fully meet the various needs of our customers by providing complete products (including design, manufacturing, and service), thereby adding value to our products. Our cost-effectiveness, high quality, short lead times, and excellent customer service enable us to meet and exceed your expectations.


The content above was translated by Ai
more ↓

Similar Companies

SLINGX CORP.

1. "CardioRenix Matrix AI Smart Care Operating System": Creating the world's first clinical biochemical signal infrastructure layer integrating "decentralized real-time diagnosis, continuous AI risk prediction, and health insurance payment mechanisms," transforming medical records into digital smart assets.
2. "Matrix929™ Real-Time Microfluidic Analyzer": The exclusive patented N-DNA™ technology successfully overcomes the "Debye Screening Wall" that has blocked the industry for 30 years. With just a single drop of whole blood at your fingertip, you can generate central laboratory-level data within 15 minutes with sensitivity reaching fM (fimolar) levels, surpassing traditional optical inspection by 1,000 times. A single cartridge can quantitatively detect eight key CKM biomarkers including hs-cTnI, NT-proBNP, and HbA1c, quantifying micro-deterioration trends in organs.
3. "EvoRisk™ AI Prediction Engine and L1 Growth Memory Layer": This is the system's digital brain. The L1 growth memory layer uses MySQL (factual memory: biochemical indicators and prescriptions), Redis (state memory: real-time follow-up progress), and Graphiti (contextual memory: causal relationship maps of complaints and indicators) to transform static medical records into dynamic medical memory. The system self-optimizes through continuous learning mechanisms, predicting major cardiovascular adverse events (MACE) within 12 months with an accuracy of up to 0.90 AUC, advancing the intervention window by 5-10 years.
4. "Dr. AI Health Companion Assistant App": Integrates localized semantic mapping (TW-RAG), automatically de-hallucinating elderly Taiwanese slang names (such as "kidney guai"), and accurately maps them into SNOMED CT (code 709044004 chronic kidney disease) international standard clinical codes. When linked to Apple Watch, if acute warning signs such as HRV/HR anomalies are detected, the UI will be force-taken within 10 seconds to trigger an emergency alert status machine and immediately notify the medical team.
回頁面最頂端